Sperimentazione in fase di reclutamento = ; Sperimentazione in corso = ; Finanziato da un ente associato a IRDiRC = ; Membro di una ERN =

Sperimentazioni cliniche nazionali

REGNO UNITO; GRAN BRETAGNA

West Midlands
BIRMINGHAM

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity

University Hospital Birmingham

Marshfield Clinic

Ulteriori dettagli

SPAGNA

Madrid
MADRID

Setmelanotide (RM-493): Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity - ES

Hospital Infantil Universitario Niño Jesús

Servicio de Endocrinología, Crecimiento y Metabolismo

Ulteriori dettagli

SPAGNA

Madrid
MADRID

A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and AlstrC6m syndrome (AS) Patients with Moderate to Severe Obesity - ES

Hospital Infantil Universitario Niño Jesús

Servicio de Endocrinología, Crecimiento y Metabolismo

Ulteriori dettagli